FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine, namely, it is aimed at treating or preventing coronavirus infection in humans or animals caused by the SARS-Cov-2 virus by using a compound of general formula 1, where R is CH3, or its hydrochloride salt, dihydrochloride salt or hexahydrate dihydrochloride.
EFFECT: high antiviral activity against coronavirus infection in humans or animals caused by the SARS-Cov-2 virus.
1
4 cl, 6 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
4,6-DI(3,12-DIAZA-6,9-DIAZONIADISPIRO[5,2,5,2]HEXADECAN-1-YL)-2-METHYL-5-NITROPYRIMIDINE TETRACHLORIDE HYDROCHLORIDE HEXAHYDARATE FOR TREATING HERPETIC INFECTION, PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION | 2014 |
|
RU2573977C9 |
PYRIMIDYL-DI(DIAZADISPIROALKANE)S WITH ANTIVIRAL ACTIVITY | 2015 |
|
RU2633699C2 |
INDOLE-3-CARBOXYLIC ACID DERIVATIVE HAVING ANTIVIRAL ACTIVITY ON SARS-CoV-2 | 2022 |
|
RU2820633C1 |
MEFLOQUINE AND COMBINATIONS THEREOF FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | 2020 |
|
RU2763024C1 |
METHOD FOR PROTECTION AGAINST CORONAVIRUS INFECTION | 2020 |
|
RU2747467C1 |
AN ANTIVIRAL AGENT AGAINST SARS-COV-2 CORONAVIRUS | 2022 |
|
RU2788762C1 |
METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
AGENT FOR REDUCING RISK AND RELIEVING SYMPTOMS OF BETA-CORONAVIRUS INFECTION | 2021 |
|
RU2747890C1 |
PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
LIPOSOMAL COMPOSITION OF 5-CHLOROPYRIDIN-3-IL-1H-INDOL-4-CARBOXYLATE AS A POTENTIAL EMERGENCY PREVENTION AND TREATMENT OF CORONAVIRUS INFECTIONS | 2023 |
|
RU2810261C1 |
Authors
Dates
2021-12-14—Published
2020-12-08—Filed